new BindingDB logo
myBDB logout
Compile Data Set for Download or QSAR

Found 1423 hits Enz. Inhib. hit(s) with Target = 'NPY5R'   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417035
PNG
(CHEMBL1257993)
Show SMILES Fc1ccccc1-c1cnc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3ccccn3)CC2)cn1 |r,wU:13.13,wD:16.22,(15.52,-7.53,;14.76,-6.18,;13.23,-6.17,;12.47,-4.82,;13.26,-3.49,;14.8,-3.52,;15.55,-4.86,;17.09,-4.88,;17.88,-3.56,;19.42,-3.58,;20.17,-4.93,;21.71,-4.96,;22.45,-6.3,;23.99,-6.33,;24.79,-5.01,;26.33,-5.03,;27.07,-6.38,;28.2,-5.34,;29.54,-6.12,;29.22,-7.62,;30.25,-8.77,;27.69,-7.78,;30.95,-5.5,;32.19,-6.4,;33.6,-5.78,;33.76,-4.25,;32.51,-3.34,;31.11,-3.97,;26.27,-7.7,;24.74,-7.67,;19.38,-6.25,;17.85,-6.23,)|
Show InChI InChI=1S/C24H24FN5O2/c25-19-6-2-1-5-18(19)20-14-29-21(15-27-20)28-13-17-8-10-24(11-9-17)16-30(23(31)32-24)22-7-3-4-12-26-22/h1-7,12,14-15,17H,8-11,13,16H2,(H,28,29)/t17-,24-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.0251n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417033
PNG
(CHEMBL1258111)
Show SMILES Fc1ccccc1-n1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3ccccn3)CC2)n1 |r,wU:13.13,wD:16.22,(15.91,-.57,;14.51,.08,;13.26,-.81,;11.85,-.16,;11.72,1.37,;12.98,2.26,;14.38,1.6,;15.63,2.49,;15.65,4.03,;17.12,4.48,;18.01,3.23,;19.55,3.2,;20.3,1.86,;21.84,1.83,;22.63,3.15,;24.17,3.13,;24.91,1.78,;26.05,2.82,;27.39,2.04,;27.06,.54,;28.09,-.61,;25.53,.38,;28.79,2.66,;30.04,1.75,;31.44,2.38,;31.61,3.91,;30.35,4.82,;28.95,4.19,;24.12,.46,;22.59,.49,;17.08,1.99,)|
Show InChI InChI=1S/C23H24FN5O2/c24-18-5-1-2-6-19(18)29-14-10-20(27-29)26-15-17-8-11-23(12-9-17)16-28(22(30)31-23)21-7-3-4-13-25-21/h1-7,10,13-14,17H,8-9,11-12,15-16H2,(H,26,27)/t17-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.0316n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417056
PNG
(CHEMBL1258225)
Show SMILES Fc1ccccc1-n1cc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cncnc3)CC2)cn1 |r,wU:12.12,wD:15.21,(-5.79,-9.02,;-7.19,-8.37,;-8.44,-9.26,;-9.85,-8.61,;-9.98,-7.07,;-8.73,-6.19,;-7.33,-6.84,;-6.08,-5.96,;-4.62,-6.46,;-3.69,-5.22,;-2.15,-5.25,;-1.4,-6.59,;.14,-6.62,;.94,-5.3,;2.48,-5.31,;3.21,-6.67,;4.35,-5.63,;5.69,-6.41,;5.37,-7.91,;6.4,-9.06,;3.84,-8.08,;7.1,-5.79,;8.34,-6.69,;9.75,-6.07,;9.91,-4.54,;8.66,-3.63,;7.26,-4.26,;2.42,-7.99,;.89,-7.96,;-4.58,-3.96,;-6.05,-4.42,)|
Show InChI InChI=1S/C22H23FN6O2/c23-19-3-1-2-4-20(19)29-13-17(10-27-29)26-9-16-5-7-22(8-6-16)14-28(21(30)31-22)18-11-24-15-25-12-18/h1-4,10-13,15-16,26H,5-9,14H2/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.0398n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417051
PNG
(CHEMBL1258787)
Show SMILES Cc1ccccc1-c1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnn3)CC2)nn1 |r,wU:13.13,wD:16.22,(17.45,-6.84,;16.7,-5.5,;15.16,-5.48,;14.41,-4.13,;15.2,-2.81,;16.74,-2.83,;17.48,-4.18,;19.03,-4.2,;19.78,-5.55,;21.32,-5.57,;22.1,-4.25,;23.64,-4.27,;24.39,-5.62,;25.93,-5.64,;26.72,-4.32,;28.26,-4.34,;29,-5.69,;30.14,-4.66,;31.48,-5.43,;31.16,-6.94,;32.19,-8.08,;29.62,-7.1,;32.88,-4.81,;34.13,-5.72,;35.54,-5.1,;35.7,-3.56,;34.44,-2.66,;33.04,-3.29,;28.21,-7.01,;26.68,-6.98,;21.36,-2.9,;19.82,-2.87,)|
Show InChI InChI=1S/C24H26N6O2/c1-17-5-2-3-6-19(17)20-8-9-21(28-27-20)25-15-18-10-12-24(13-11-18)16-30(23(31)32-24)22-7-4-14-26-29-22/h2-9,14,18H,10-13,15-16H2,1H3,(H,25,28)/t18-,24-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.0631n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417045
PNG
(CHEMBL1258341)
Show SMILES Fc1ccccc1-n1cc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cnccn3)CC2)cn1 |r,wU:12.12,wD:15.21,(-6.54,-17.19,;-7.94,-16.54,;-9.19,-17.43,;-10.59,-16.78,;-10.73,-15.24,;-9.48,-14.36,;-8.08,-15.01,;-6.82,-14.13,;-5.37,-14.63,;-4.44,-13.39,;-2.9,-13.41,;-2.15,-14.76,;-.61,-14.79,;.19,-13.47,;1.73,-13.48,;2.46,-14.84,;3.6,-13.8,;4.94,-14.58,;4.62,-16.08,;5.64,-17.23,;3.09,-16.24,;6.35,-13.96,;7.58,-14.86,;8.99,-14.24,;9.15,-12.71,;7.91,-11.8,;6.5,-12.43,;1.67,-16.16,;.14,-16.13,;-5.33,-12.13,;-6.8,-12.59,)|
Show InChI InChI=1S/C22H23FN6O2/c23-18-3-1-2-4-19(18)29-14-17(12-27-29)26-11-16-5-7-22(8-6-16)15-28(21(30)31-22)20-13-24-9-10-25-20/h1-4,9-10,12-14,16,26H,5-8,11,15H2/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.0631n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417036
PNG
(CHEMBL1257992)
Show SMILES Fc1ccccc1-c1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3ccccn3)CC2)nn1 |r,wU:13.13,wD:16.22,(-7.93,-14.34,;-8.69,-13,;-10.22,-12.98,;-10.98,-11.63,;-10.19,-10.31,;-8.65,-10.33,;-7.9,-11.68,;-6.36,-11.69,;-5.6,-13.04,;-4.07,-13.06,;-3.28,-11.75,;-1.74,-11.77,;-1,-13.12,;.54,-13.14,;1.34,-11.82,;2.88,-11.84,;3.62,-13.19,;4.75,-12.16,;6.09,-12.93,;5.77,-14.44,;6.8,-15.58,;4.24,-14.6,;7.5,-12.31,;8.74,-13.22,;10.15,-12.59,;10.31,-11.06,;9.06,-10.15,;7.66,-10.78,;2.82,-14.51,;1.29,-14.48,;-4.03,-10.4,;-5.57,-10.37,)|
Show InChI InChI=1S/C24H24FN5O2/c25-19-6-2-1-5-18(19)20-8-9-21(29-28-20)27-15-17-10-12-24(13-11-17)16-30(23(31)32-24)22-7-3-4-14-26-22/h1-9,14,17H,10-13,15-16H2,(H,27,29)/t17-,24-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.0631n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417032
PNG
(CHEMBL1258110)
Show SMILES O=C1O[C@@]2(CN1c1ccccn1)CC[C@H](CNc1nc(cs1)-c1ccccn1)CC2 |r,wU:14.16,wD:3.2,(5.76,.15,;4.73,1.3,;3.2,1.14,;2.57,2.54,;3.71,3.58,;5.05,2.8,;6.45,3.43,;7.7,2.52,;9.11,3.14,;9.27,4.67,;8.02,5.58,;6.61,4.95,;1.83,3.89,;.29,3.91,;-.5,2.59,;-2.04,2.62,;-2.79,3.96,;-4.33,3.99,;-5.25,2.75,;-6.71,3.25,;-6.69,4.79,;-5.21,5.24,;-7.96,2.37,;-7.82,.84,;-9.08,-.05,;-10.48,.6,;-10.62,2.14,;-9.36,3.02,;.25,1.25,;1.78,1.22,)|
Show InChI InChI=1S/C22H23N5O2S/c28-21-27(19-6-2-4-12-24-19)15-22(29-21)9-7-16(8-10-22)13-25-20-26-18(14-30-20)17-5-1-3-11-23-17/h1-6,11-12,14,16H,7-10,13,15H2,(H,25,26)/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.0794n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417050
PNG
(CHEMBL1258674)
Show SMILES Fc1cc(F)cc(c1)-c1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnn3)CC2)nn1 |r,wU:14.14,wD:17.23,(-9.07,-1.62,;-8.32,-2.96,;-9.11,-4.29,;-8.36,-5.64,;-9.14,-6.96,;-6.82,-5.65,;-6.04,-4.34,;-6.78,-2.99,;-4.49,-4.35,;-3.74,-5.7,;-2.2,-5.72,;-1.42,-4.4,;.12,-4.43,;.87,-5.77,;2.41,-5.8,;3.2,-4.48,;4.74,-4.5,;5.48,-5.85,;6.62,-4.81,;7.96,-5.59,;7.64,-7.09,;8.67,-8.24,;6.1,-7.25,;9.36,-4.97,;10.61,-5.88,;12.02,-5.25,;12.18,-3.72,;10.92,-2.81,;9.52,-3.44,;4.69,-7.17,;3.16,-7.14,;-2.16,-3.06,;-3.7,-3.03,)|
Show InChI InChI=1S/C23H22F2N6O2/c24-17-10-16(11-18(25)12-17)19-3-4-20(29-28-19)26-13-15-5-7-23(8-6-15)14-31(22(32)33-23)21-2-1-9-27-30-21/h1-4,9-12,15H,5-8,13-14H2,(H,26,29)/t15-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.100n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417046
PNG
(CHEMBL1258453)
Show SMILES Fc1ccccc1-n1cc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnn3)CC2)cn1 |r,wU:12.12,wD:15.21,(16.1,-16.72,;14.7,-16.07,;13.45,-16.97,;12.04,-16.31,;11.91,-14.78,;13.16,-13.9,;14.56,-14.55,;15.81,-13.67,;17.27,-14.16,;18.2,-12.92,;19.74,-12.95,;20.49,-14.3,;22.03,-14.32,;22.82,-13,;24.36,-13.02,;25.1,-14.37,;26.24,-13.33,;27.58,-14.11,;27.26,-15.62,;28.28,-16.76,;25.73,-15.78,;28.99,-13.49,;30.23,-14.4,;31.63,-13.78,;31.8,-12.24,;30.55,-11.33,;29.15,-11.97,;24.31,-15.69,;22.78,-15.66,;17.31,-11.67,;15.84,-12.13,)|
Show InChI InChI=1S/C22H23FN6O2/c23-18-4-1-2-5-19(18)29-14-17(13-26-29)24-12-16-7-9-22(10-8-16)15-28(21(30)31-22)20-6-3-11-25-27-20/h1-6,11,13-14,16,24H,7-10,12,15H2/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.100n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417044
PNG
(CHEMBL1258340)
Show SMILES Fc1ccccc1-n1cc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnc3F)CC2)cn1 |r,wU:12.12,wD:15.21,(17.14,-9.3,;15.74,-8.65,;14.5,-9.54,;13.09,-8.89,;12.95,-7.35,;14.21,-6.47,;15.61,-7.12,;16.86,-6.24,;18.32,-6.74,;19.25,-5.5,;20.79,-5.52,;21.54,-6.87,;23.08,-6.9,;23.87,-5.57,;25.41,-5.59,;26.15,-6.95,;27.29,-5.92,;28.63,-6.69,;28.31,-8.19,;29.34,-9.34,;26.78,-8.35,;30.04,-6.07,;31.28,-6.97,;32.69,-6.35,;32.85,-4.82,;31.6,-3.91,;30.2,-4.54,;28.95,-3.63,;25.36,-8.27,;23.83,-8.24,;18.36,-4.24,;16.89,-4.7,)|
Show InChI InChI=1S/C23H23F2N5O2/c24-18-4-1-2-5-19(18)30-14-17(13-28-30)27-12-16-7-9-23(10-8-16)15-29(22(31)32-23)20-6-3-11-26-21(20)25/h1-6,11,13-14,16,27H,7-10,12,15H2/t16-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.100n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417042
PNG
(CHEMBL1257636)
Show SMILES Fc1ccccc1-n1cc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnc3)CC2)cn1 |r,wU:12.12,wD:15.21,(-7.01,-.66,;-8.41,-.01,;-9.65,-.9,;-11.06,-.25,;-11.21,1.29,;-9.94,2.17,;-8.54,1.52,;-7.29,2.4,;-5.83,1.9,;-4.9,3.14,;-3.36,3.12,;-2.62,1.77,;-1.08,1.74,;-.28,3.07,;1.26,3.05,;2,1.7,;3.14,2.73,;4.48,1.96,;4.16,.45,;5.18,-.7,;2.62,.29,;5.88,2.57,;7.12,1.67,;8.53,2.29,;8.69,3.82,;7.44,4.73,;6.04,4.1,;1.21,.37,;-.33,.41,;-5.79,4.4,;-7.27,3.94,)|
Show InChI InChI=1S/C23H24FN5O2/c24-20-5-1-2-6-21(20)29-15-18(13-27-29)26-12-17-7-9-23(10-8-17)16-28(22(30)31-23)19-4-3-11-25-14-19/h1-6,11,13-15,17,26H,7-10,12,16H2/t17-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.100n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417041
PNG
(CHEMBL1257637)
Show SMILES O=C1O[C@@]2(CN1c1ccccn1)CC[C@H](CNc1ccc(cn1)-c1nccs1)CC2 |r,wU:14.16,wD:3.2,(30.13,-31.33,;29.1,-30.19,;27.57,-30.35,;26.95,-28.94,;28.09,-27.91,;29.43,-28.68,;30.83,-28.06,;32.08,-28.97,;33.48,-28.34,;33.65,-26.81,;32.39,-25.9,;30.99,-26.53,;26.21,-27.59,;24.67,-27.57,;23.88,-28.89,;22.34,-28.87,;21.59,-27.52,;20.05,-27.5,;19.26,-28.81,;17.73,-28.79,;16.97,-27.44,;17.77,-26.12,;19.3,-26.15,;15.43,-27.43,;14.51,-28.66,;13.05,-28.17,;13.06,-26.63,;14.53,-26.17,;24.62,-30.23,;26.16,-30.26,)|
Show InChI InChI=1S/C22H23N5O2S/c28-21-27(19-3-1-2-10-23-19)15-22(29-21)8-6-16(7-9-22)13-25-18-5-4-17(14-26-18)20-24-11-12-30-20/h1-5,10-12,14,16H,6-9,13,15H2,(H,25,26)/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.126n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417054
PNG
(CHEMBL1258673)
Show SMILES Fc1ccccc1-c1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnn3)CC2)nn1 |r,wU:13.13,wD:16.22,(14.72,.44,;13.96,1.78,;12.43,1.8,;11.67,3.15,;12.46,4.47,;14,4.45,;14.75,3.1,;16.29,3.08,;17.04,1.73,;18.58,1.71,;19.36,3.03,;20.9,3.01,;21.65,1.66,;23.19,1.64,;23.99,2.96,;25.53,2.94,;26.26,1.59,;27.4,2.62,;28.74,1.85,;28.42,.34,;29.45,-.8,;26.89,.18,;30.15,2.47,;31.39,1.56,;32.8,2.18,;32.96,3.72,;31.71,4.62,;30.31,3.99,;25.47,.27,;23.94,.3,;18.62,4.38,;17.08,4.41,)|
Show InChI InChI=1S/C23H23FN6O2/c24-18-5-2-1-4-17(18)19-7-8-20(28-27-19)25-14-16-9-11-23(12-10-16)15-30(22(31)32-23)21-6-3-13-26-29-21/h1-8,13,16H,9-12,14-15H2,(H,25,28)/t16-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.158n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417390
PNG
(CHEMBL1289154)
Show SMILES FC(F)(F)Oc1ccc2nc([nH]c2c1)N1CCC2(CN(C(=O)O2)c2ccccc2)CC1
Show InChI InChI=1S/C21H19F3N4O3/c22-21(23,24)30-15-6-7-16-17(12-15)26-18(25-16)27-10-8-20(9-11-27)13-28(19(29)31-20)14-4-2-1-3-5-14/h1-7,12H,8-11,13H2,(H,25,26)
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.158n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417040
PNG
(CHEMBL1257760)
Show SMILES O=C1O[C@@]2(CN1c1ccccn1)CC[C@H](CNc1ccc(cn1)-c1ncccn1)CC2 |r,wU:14.16,wD:3.2,(7.1,-28.95,;6.07,-27.81,;4.54,-27.97,;3.92,-26.56,;5.06,-25.53,;6.4,-26.3,;7.8,-25.68,;9.05,-26.59,;10.45,-25.96,;10.62,-24.43,;9.36,-23.52,;7.96,-24.15,;3.18,-25.21,;1.64,-25.19,;.85,-26.51,;-.69,-26.49,;-1.44,-25.14,;-2.98,-25.12,;-3.77,-26.43,;-5.3,-26.41,;-6.06,-25.06,;-5.26,-23.74,;-3.73,-23.77,;-7.6,-25.05,;-8.35,-23.7,;-9.89,-23.68,;-10.68,-25,;-9.92,-26.35,;-8.38,-26.37,;1.59,-27.85,;3.13,-27.88,)|
Show InChI InChI=1S/C23H24N6O2/c30-22-29(20-4-1-2-11-24-20)16-23(31-22)9-7-17(8-10-23)14-27-19-6-5-18(15-28-19)21-25-12-3-13-26-21/h1-6,11-13,15,17H,7-10,14,16H2,(H,27,28)/t17-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.158n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417039
PNG
(CHEMBL1257761)
Show SMILES O=C1O[C@@]2(CN1c1ccccn1)CC[C@H](CNc1ccc(OC3CCC3)cn1)CC2 |r,wU:14.16,wD:3.2,(29.67,-25.14,;28.64,-23.99,;27.1,-24.16,;26.48,-22.75,;27.62,-21.72,;28.96,-22.49,;30.36,-21.87,;31.61,-22.78,;33.02,-22.15,;33.18,-20.62,;31.92,-19.71,;30.52,-20.34,;25.74,-21.4,;24.2,-21.38,;23.41,-22.7,;21.87,-22.68,;21.12,-21.33,;19.58,-21.3,;18.8,-22.62,;17.26,-22.6,;16.51,-21.25,;14.96,-21.24,;14.22,-19.89,;14.64,-18.41,;13.16,-17.99,;12.74,-19.47,;17.3,-19.93,;18.84,-19.96,;24.16,-24.04,;25.69,-24.07,)|
Show InChI InChI=1S/C23H28N4O3/c28-22-27(21-6-1-2-13-24-21)16-23(30-22)11-9-17(10-12-23)14-25-20-8-7-19(15-26-20)29-18-4-3-5-18/h1-2,6-8,13,15,17-18H,3-5,9-12,14,16H2,(H,25,26)/t17-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.158n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417048
PNG
(CHEMBL1258562)
Show SMILES Cc1nnc(s1)N1C[C@@]2(CC[C@H](CNc3cnn(c3)-c3ccccc3F)CC2)OC1=O |r,wU:11.12,wD:8.31,(32.21,-20.6,;30.68,-20.6,;29.77,-19.35,;28.3,-19.82,;28.3,-21.36,;29.77,-21.84,;26.9,-21.98,;25.57,-21.2,;24.42,-22.24,;23.69,-20.88,;22.15,-20.86,;21.35,-22.19,;19.81,-22.16,;19.07,-20.81,;17.53,-20.79,;16.64,-19.53,;15.17,-19.99,;15.14,-21.53,;16.6,-22.03,;13.89,-22.41,;12.49,-21.76,;11.24,-22.64,;11.37,-24.18,;12.78,-24.83,;14.02,-23.94,;15.42,-24.59,;22.1,-23.53,;23.64,-23.56,;25.05,-23.64,;26.58,-23.48,;27.61,-24.63,)|
Show InChI InChI=1S/C21H23FN6O2S/c1-14-25-26-19(31-14)27-13-21(30-20(27)29)8-6-15(7-9-21)10-23-16-11-24-28(12-16)18-5-3-2-4-17(18)22/h2-5,11-12,15,23H,6-10,13H2,1H3/t15-,21-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.200n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417047
PNG
(CHEMBL1258454)
Show SMILES Fc1ccccc1-n1cc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3ccnnc3)CC2)cn1 |r,wU:12.12,wD:15.21,(-7.1,-25.51,;-8.5,-24.86,;-9.75,-25.75,;-11.16,-25.1,;-11.3,-23.56,;-10.04,-22.68,;-8.64,-23.33,;-7.38,-22.45,;-5.93,-22.95,;-5,-21.71,;-3.45,-21.73,;-2.71,-23.08,;-1.17,-23.1,;-.37,-21.78,;1.17,-21.8,;1.9,-23.15,;3.04,-22.12,;4.38,-22.89,;4.06,-24.4,;5.09,-25.55,;2.53,-24.56,;5.79,-22.28,;7.03,-23.18,;8.44,-22.56,;8.6,-21.03,;7.35,-20.12,;5.95,-20.75,;1.11,-24.48,;-.42,-24.44,;-5.89,-20.45,;-7.36,-20.91,)|
Show InChI InChI=1S/C22H23FN6O2/c23-19-3-1-2-4-20(19)29-14-17(12-27-29)24-11-16-5-8-22(9-6-16)15-28(21(30)31-22)18-7-10-25-26-13-18/h1-4,7,10,12-14,16,24H,5-6,8-9,11,15H2/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.200n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417407
PNG
(CHEMBL1289153)
Show SMILES Fc1ccc(cc1)-c1ccc2[nH]c(nc2c1)N1CCC2(CN(C(=O)O2)c2ccccc2)CC1
Show InChI InChI=1S/C26H23FN4O2/c27-20-9-6-18(7-10-20)19-8-11-22-23(16-19)29-24(28-22)30-14-12-26(13-15-30)17-31(25(32)33-26)21-4-2-1-3-5-21/h1-11,16H,12-15,17H2,(H,28,29)
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.200n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
NPY5R


(Chicken)
BDBM82276
PNG
(L31,P34-NPY,human | NPY Leu31, Pro34, human, rat |...)
Show InChI InChI=1S/C188H282N54O56S/c1-15-94(8)148(178(292)231-127(81-139(191)251)165(279)223-122(74-92(4)5)168(282)235-147(93(6)7)177(291)237-149(99(13)245)179(293)220-119(31-21-66-206-188(200)201)183(297)241-70-25-35-137(241)174(288)218-114(30-20-65-205-187(198)199)155(269)221-120(150(193)264)76-101-39-49-107(247)50-40-101)236-169(283)125(79-104-45-55-110(250)56-46-104)226-164(278)126(80-105-86-202-90-208-105)227-157(271)113(29-19-64-204-186(196)197)216-161(275)121(73-91(2)3)222-153(267)96(10)210-170(284)132(88-243)233-163(277)124(78-103-43-53-109(249)54-44-103)225-162(276)123(77-102-41-51-108(248)52-42-102)224-156(270)112(28-18-63-203-185(194)195)214-151(265)95(9)209-154(268)117(61-72-299-14)217-166(280)129(84-145(260)261)229-159(273)116(58-60-143(256)257)215-152(266)97(11)211-173(287)135-33-23-67-238(135)180(294)98(12)212-160(274)128(83-144(258)259)228-158(272)115(57-59-142(254)255)213-141(253)87-207-172(286)134-32-22-69-240(134)184(298)131(82-140(192)252)232-167(281)130(85-146(262)263)230-175(289)138-36-26-71-242(138)182(296)118(27-16-17-62-189)219-171(285)133(89-244)234-176(290)136-34-24-68-239(136)181(295)111(190)75-100-37-47-106(246)48-38-100/h37-56,86,90-99,111-138,147-149,243-250H,15-36,57-85,87-89,189-190H2,1-14H3,(H2,191,251)(H2,192,252)(H2,193,264)(H,202,208)(H,207,286)(H,209,268)(H,210,284)(H,211,287)(H,212,274)(H,213,253)(H,214,265)(H,215,266)(H,216,275)(H,217,280)(H,218,288)(H,219,285)(H,220,293)(H,221,269)(H,222,267)(H,223,279)(H,224,270)(H,225,276)(H,226,278)(H,227,271)(H,228,272)(H,229,273)(H,230,289)(H,231,292)(H,232,281)(H,233,277)(H,234,290)(H,235,282)(H,236,283)(H,237,291)(H,254,255)(H,256,257)(H,258,259)(H,260,261)(H,262,263)(H4,194,195,203)(H4,196,197,204)(H4,198,199,205)(H4,200,201,206)/t94-,95-,96-,97-,98-,99+,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,147-,148-,149-/m0/s1
KEGG

UniProtKB/TrEMBL

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.210n/an/an/an/an/an/an/an/a



Uppsala University

Curated by PDSP Ki Database




J Neurochem 81: 462-71 (2002)


Article DOI: 10.1046/j.1471-4159.2002.00817.x
BindingDB Entry DOI: 10.7270/Q2T72G1G
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM85680
PNG
(PP [cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34], hu...)
Show SMILES [#6]-[#6]-[#6](-[#6])-[#6@H](-[#7]-[#6](=O)-[#7](-[#6]-c1ccc(-[#8])cc1)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]\[#7+]=[#6](/[#7])-[#7])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#6])-[#6])-[#7]-[#6](=O)-[#6@H](-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#8])-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccc(-[#8])cc1)-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccc(-[#8])cc1)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#7]-[#6](=O)-[#6@H](-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#16]-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#8])=O)-[#7]-[#6](=O)-[#6@@H]-1-[#6]-[#6]-[#6]-[#7]-1-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#8])=O)-[#7]-[#6](=O)-[#6]-[#7]-[#6](=O)-[#6@@H]-1-[#6]-[#6]-[#6]-[#7]-1-[#6](=O)-[#6@H](-[#6]-c1ccc(-[#8])cc1)-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@@H]-1-[#6]-[#6]-[#6]-[#7]-1-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#8])-[#7]-[#6](=O)-[#6@@H]-1-[#6]-[#6]-[#6]-[#7]-1-[#6](=O)-[#6]-[#7])-[#6](-[#6])-[#8])-[#6](-[#6])-[#8])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#7])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#16]-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6])-[#6](=O)-[#7]C([#6])([#6])[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6](-[#7])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](-[#7])=O
Show InChI InChI=1S/C182H280N58O54S2/c1-15-89(4)140(170(288)226-122(81-135(188)254)161(279)218-115(63-74-296-14)149(267)209-93(8)147(265)234-182(11,12)175(293)230-109(28-19-67-203-179(196)197)153(271)215-111(54-58-131(184)250)154(272)212-108(27-18-66-202-178(194)195)151(269)221-117(143(189)261)76-96-34-44-101(245)45-35-96)233-181(294)240(85-100-42-52-105(249)53-43-100)235-165(283)110(29-20-68-204-180(198)199)214-150(268)107(26-17-65-201-177(192)193)213-158(276)118(75-88(2)3)222-145(263)91(6)208-163(281)125(86-241)228-160(278)120(78-98-38-48-103(247)49-39-98)224-159(277)119(77-97-36-46-102(246)47-37-97)223-152(270)106(25-16-64-200-176(190)191)211-144(262)90(5)206-148(266)114(62-73-295-13)217-155(273)112(55-59-132(185)251)216-156(274)113(57-61-138(257)258)219-168(286)129-32-24-72-239(129)174(292)142(95(10)244)232-146(264)92(7)207-157(275)121(80-134(187)253)225-162(280)123(82-139(259)260)210-136(255)84-205-166(284)127-30-22-70-237(127)173(291)124(79-99-40-50-104(248)51-41-99)227-171(289)141(94(9)243)231-169(287)130-33-23-71-238(130)172(290)116(56-60-133(186)252)220-164(282)126(87-242)229-167(285)128-31-21-69-236(128)137(256)83-183/h34-53,88-95,106-130,140-142,241-249H,15-33,54-87,183H2,1-14H3,(H2,184,250)(H2,185,251)(H2,186,252)(H2,187,253)(H2,188,254)(H2,189,261)(H,205,284)(H,206,266)(H,207,275)(H,208,281)(H,209,267)(H,210,255)(H,211,262)(H,212,272)(H,213,276)(H,214,268)(H,215,271)(H,216,274)(H,217,273)(H,218,279)(H,219,286)(H,220,282)(H,221,269)(H,222,263)(H,223,270)(H,224,277)(H,225,280)(H,226,288)(H,227,289)(H,228,278)(H,229,285)(H,230,293)(H,231,287)(H,232,264)(H,233,294)(H,234,265)(H,235,283)(H,257,258)(H,259,260)(H4,190,191,200)(H4,192,193,201)(H4,194,195,202)(H4,196,197,203)(H4,198,199,204)/p+1/t89?,90-,91-,92-,93-,94?,95?,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,140-,141-,142-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.240n/an/an/an/an/an/an/an/a



Federal Institute of Technology of Zurich

Curated by PDSP Ki Database




J Biol Chem 275: 36043-8 (2000)


Article DOI: 10.1074/jbc.M000626200
BindingDB Entry DOI: 10.7270/Q2PV6HX1
More data for this
Ligand-Target Pair
NPY5R


(Chicken)
BDBM50089038
PNG
(CGP 71683 | CGP-71683A | CHEMBL17645 | N-{[(1r,4r)...)
Show SMILES Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |wU:6.5,wD:9.9,(2.92,.42,;2.94,-1.13,;4.28,-1.89,;4.29,-3.44,;5.63,-4.22,;6.96,-3.45,;8.29,-4.21,;9.63,-3.44,;10.96,-4.22,;10.95,-5.76,;12.28,-6.54,;13.77,-6.13,;14.86,-7.21,;13.98,-8.47,;15.7,-5.91,;16.12,-8.05,;17.24,-7,;18.73,-7.45,;19.09,-8.94,;17.97,-9.99,;18.33,-11.48,;17.22,-12.56,;15.73,-12.11,;15.38,-10.62,;16.49,-9.56,;9.62,-6.51,;8.29,-5.75,;2.95,-4.23,;1.61,-3.45,;.26,-4.23,;-1.07,-3.46,;-1.07,-1.9,;.26,-1.13,;1.61,-1.9,)|
Show InChI InChI=1S/C26H29N5O2S/c27-25-22-9-3-4-10-23(22)30-26(31-25)28-16-18-12-14-19(15-13-18)17-29-34(32,33)24-11-5-7-20-6-1-2-8-21(20)24/h1-11,18-19,29H,12-17H2,(H3,27,28,30,31)/t18-,19-
KEGG

UniProtKB/TrEMBL

GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
0.240n/an/an/an/an/an/an/an/a



Uppsala University

Curated by PDSP Ki Database




J Neurochem 81: 462-71 (2002)


Article DOI: 10.1046/j.1471-4159.2002.00817.x
BindingDB Entry DOI: 10.7270/Q2T72G1G
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417055
PNG
(CHEMBL1258788)
Show SMILES Cc1cccc(n1)-c1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnn3)CC2)nc1 |r,wU:13.13,wD:16.22,(-8.85,-9.35,;-8.11,-10.7,;-8.9,-12.02,;-8.14,-13.37,;-6.6,-13.38,;-5.82,-12.07,;-6.57,-10.72,;-4.28,-12.08,;-3.52,-13.43,;-1.98,-13.45,;-1.2,-12.13,;.34,-12.16,;1.09,-13.51,;2.63,-13.53,;3.42,-12.21,;4.96,-12.23,;5.7,-13.58,;6.84,-12.55,;8.18,-13.32,;7.85,-14.82,;8.88,-15.97,;6.32,-14.99,;9.58,-12.7,;10.83,-13.61,;12.23,-12.98,;12.4,-11.45,;11.14,-10.54,;9.74,-11.17,;4.91,-14.9,;3.37,-14.87,;-1.95,-10.79,;-3.48,-10.76,)|
Show InChI InChI=1S/C24H26N6O2/c1-17-4-2-5-20(28-17)19-7-8-21(26-15-19)25-14-18-9-11-24(12-10-18)16-30(23(31)32-24)22-6-3-13-27-29-22/h2-8,13,15,18H,9-12,14,16H2,1H3,(H,25,26)/t18-,24-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.251n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
NPY5R


(Chicken)
BDBM50005530
PNG
(CHEMBL267633 | D-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-G...)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O |r|
Show InChI InChI=1S/C190H287N55O57/c1-16-94(9)149(180(296)235-129(81-141(194)255)169(285)227-124(74-93(7)8)172(288)240-150(95(10)17-2)181(297)241-151(100(15)248)182(298)222-116(32-23-67-209-190(203)204)156(272)221-118(57-60-140(193)254)161(277)219-114(30-21-65-207-188(199)200)157(273)224-121(152(196)268)76-102-39-49-108(250)50-40-102)239-173(289)127(79-105-45-55-111(253)56-46-105)230-168(284)128(80-106-86-205-90-211-106)231-159(275)115(31-22-66-208-189(201)202)220-165(281)123(73-92(5)6)225-155(271)97(12)213-174(290)134(88-246)237-167(283)126(78-104-43-53-110(252)54-44-104)229-166(282)125(77-103-41-51-109(251)52-42-103)228-158(274)113(29-20-64-206-187(197)198)217-153(269)96(11)212-163(279)122(72-91(3)4)226-170(286)131(84-147(264)265)233-162(278)119(59-62-145(260)261)218-154(270)98(13)214-177(293)137-34-25-68-242(137)183(299)99(14)215-164(280)130(83-146(262)263)232-160(276)117(58-61-144(258)259)216-143(257)87-210-176(292)136-33-24-70-244(136)186(302)133(82-142(195)256)236-171(287)132(85-148(266)267)234-178(294)139-36-27-71-245(139)185(301)120(28-18-19-63-191)223-175(291)135(89-247)238-179(295)138-35-26-69-243(138)184(300)112(192)75-101-37-47-107(249)48-38-101/h37-56,86,90-100,112-139,149-151,246-253H,16-36,57-85,87-89,191-192H2,1-15H3,(H2,193,254)(H2,194,255)(H2,195,256)(H2,196,268)(H,205,211)(H,210,292)(H,212,279)(H,213,290)(H,214,293)(H,215,280)(H,216,257)(H,217,269)(H,218,270)(H,219,277)(H,220,281)(H,221,272)(H,222,298)(H,223,291)(H,224,273)(H,225,271)(H,226,286)(H,227,285)(H,228,274)(H,229,282)(H,230,284)(H,231,275)(H,232,276)(H,233,278)(H,234,294)(H,235,296)(H,236,287)(H,237,283)(H,238,295)(H,239,289)(H,240,288)(H,241,297)(H,258,259)(H,260,261)(H,262,263)(H,264,265)(H,266,267)(H4,197,198,206)(H4,199,200,207)(H4,201,202,208)(H4,203,204,209)/t94-,95-,96-,97-,98-,99-,100+,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,149-,150-,151-/m0/s1
KEGG

UniProtKB/TrEMBL

GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.280n/an/an/an/an/an/an/an/a



Uppsala University

Curated by PDSP Ki Database




J Neurochem 81: 462-71 (2002)


Article DOI: 10.1046/j.1471-4159.2002.00817.x
BindingDB Entry DOI: 10.7270/Q2T72G1G
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50379608
PNG
(CHEMBL2013020)
Show SMILES CC(C)S(=O)(=O)NC[C@H]1CC[C@@H](CC1)NC(=O)Cn1ccc2cc(Cl)ccc12 |r,wU:8.7,wD:11.14,(12.87,-43.9,;11.53,-43.13,;11.53,-41.59,;10.2,-43.89,;10.96,-45.22,;9.43,-45.22,;8.86,-43.13,;7.53,-43.9,;6.2,-43.12,;4.87,-43.89,;3.54,-43.12,;3.54,-41.58,;4.87,-40.8,;6.2,-41.58,;2.2,-40.82,;.87,-41.59,;.88,-43.13,;-.46,-40.82,;-1.8,-41.6,;-1.96,-43.13,;-3.47,-43.45,;-4.24,-42.12,;-5.74,-41.81,;-6.22,-40.35,;-7.73,-40.04,;-5.19,-39.2,;-3.68,-39.52,;-3.21,-40.98,)|
Show InChI InChI=1S/C20H28ClN3O3S/c1-14(2)28(26,27)22-12-15-3-6-18(7-4-15)23-20(25)13-24-10-9-16-11-17(21)5-8-19(16)24/h5,8-11,14-15,18,22H,3-4,6-7,12-13H2,1-2H3,(H,23,25)/t15-,18-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.300n/an/an/an/an/an/an/an/a



Lundbeck Research USA

Curated by ChEMBL


Assay Description
Displacement of [125I]peptide YY from human NPY5 receptor


Bioorg Med Chem Lett 22: 2167-71 (2012)


Article DOI: 10.1016/j.bmcl.2012.01.117
BindingDB Entry DOI: 10.7270/Q2BV7HNQ
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50353148
PNG
(CHEMBL1829320)
Show SMILES CC(C)S(=O)(=O)NC[C@H]1CC[C@@H](CC1)NC(=O)CN1C(=O)COc2cc(Cl)ccc12 |r,wU:11.14,wD:8.7,(10,-2.04,;8.67,-1.27,;8.67,.27,;7.34,-2.03,;6.55,-3.36,;8.09,-3.36,;6.01,-1.26,;4.67,-2.02,;3.34,-1.25,;3.34,.29,;2,1.07,;.67,.29,;.67,-1.25,;2,-2.02,;-.66,1.06,;-1.99,.28,;-1.99,-1.26,;-3.33,1.06,;-4.66,.28,;-4.66,-1.26,;-3.33,-2.03,;-6,-2.03,;-7.33,-1.26,;-7.33,.27,;-8.67,1.04,;-8.67,2.59,;-10,3.35,;-7.34,3.36,;-6,2.6,;-5.99,1.05,)|
Show InChI InChI=1S/C20H28ClN3O5S/c1-13(2)30(27,28)22-10-14-3-6-16(7-4-14)23-19(25)11-24-17-8-5-15(21)9-18(17)29-12-20(24)26/h5,8-9,13-14,16,22H,3-4,6-7,10-12H2,1-2H3,(H,23,25)/t14-,16-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.300n/an/an/an/an/an/an/an/a



Lundbeck Research USA

Curated by ChEMBL


Assay Description
Displacement of [125I]peptide YY from human NPY5 receptor


Bioorg Med Chem Lett 22: 2167-71 (2012)


Article DOI: 10.1016/j.bmcl.2012.01.117
BindingDB Entry DOI: 10.7270/Q2BV7HNQ
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50128931
PNG
(CHEMBL61880 | N-(9-Isobutyl-9H-carbazol-3-yl)-3-py...)
Show SMILES CC(C)Cn1c2ccccc2c2cc(NC(=O)CCN3CCCC3)ccc12
Show InChI InChI=1S/C23H29N3O/c1-17(2)16-26-21-8-4-3-7-19(21)20-15-18(9-10-22(20)26)24-23(27)11-14-25-12-5-6-13-25/h3-4,7-10,15,17H,5-6,11-14,16H2,1-2H3,(H,24,27)
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
PubMed
0.300n/an/an/an/an/an/an/an/a



Pfizer Global Research and Development

Curated by ChEMBL


Assay Description
Binding affinity towards human neuropeptide Y receptor type 5 using 125[I]-PYY as radioligand


Bioorg Med Chem Lett 13: 1989-92 (2003)


BindingDB Entry DOI: 10.7270/Q2057F9D
More data for this
Ligand-Target Pair
NPY5R


(Chicken)
BDBM84998
PNG
(NPY 3-36, porcine)
Show InChI InChI=1S/C194H295N53O58/c1-17-101(12)155(241-182(294)144-37-25-73-244(144)187(299)117(196)82-106-39-49-112(251)50-40-106)184(296)224-125(29-18-19-67-195)188(300)245-74-27-36-143(245)181(293)222-122(60-64-151(261)262)159(271)216-104(15)186(298)243-72-24-34-141(243)179(291)212-92-148(258)217-121(59-63-150(259)260)163(275)237-138(90-154(267)268)167(279)215-103(14)158(270)240-149(94-249)305(304)247-76-28-38-145(247)183(295)223-124(62-66-153(265)266)164(276)220-123(61-65-152(263)264)165(277)226-128(78-97(4)5)170(282)235-136(88-146(197)256)175(287)219-118(30-20-68-208-191(199)200)160(272)231-133(84-108-43-53-114(253)54-44-108)173(285)232-132(83-107-41-51-113(252)52-42-107)166(278)214-102(13)157(269)239-140(93-248)178(290)230-127(77-96(2)3)168(280)218-119(31-21-69-209-192(201)202)161(273)234-135(87-111-91-207-95-213-111)174(286)233-134(85-109-45-55-115(254)56-46-109)172(284)227-130(80-99(8)9)171(283)236-137(89-147(198)257)176(288)228-129(79-98(6)7)169(281)229-131(81-100(10)11)177(289)242-156(105(16)250)185(297)225-126(33-23-71-211-194(205)206)189(301)246-75-26-35-142(246)180(292)221-120(32-22-70-210-193(203)204)162(274)238-139(190(302)303)86-110-47-57-116(255)58-48-110/h39-58,91,95-105,117-145,149,155-156,248-255H,17-38,59-90,92-94,195-196H2,1-16H3,(H2,197,256)(H2,198,257)(H,207,213)(H,212,291)(H,214,278)(H,215,279)(H,216,271)(H,217,258)(H,218,280)(H,219,287)(H,220,276)(H,221,292)(H,222,293)(H,223,295)(H,224,296)(H,225,297)(H,226,277)(H,227,284)(H,228,288)(H,229,281)(H,230,290)(H,231,272)(H,232,285)(H,233,286)(H,234,273)(H,235,282)(H,236,283)(H,237,275)(H,238,274)(H,239,269)(H,240,270)(H,241,294)(H,242,289)(H,259,260)(H,261,262)(H,263,264)(H,265,266)(H,267,268)(H,302,303)(H4,199,200,208)(H4,201,202,209)(H4,203,204,210)(H4,205,206,211)/t101?,102-,103-,104-,105+,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,149+,155-,156-/m0/s1
KEGG

UniProtKB/TrEMBL

GoogleScholar
AffyNet 
KEGG
PC cid
PC sid
UniChem
Article
PubMed
0.310n/an/an/an/an/an/an/an/a



Uppsala University

Curated by PDSP Ki Database




J Neurochem 81: 462-71 (2002)


Article DOI: 10.1046/j.1471-4159.2002.00817.x
BindingDB Entry DOI: 10.7270/Q2T72G1G
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417406
PNG
(CHEMBL1290037)
Show SMILES O=C1O[C@@]2(CN1c1ccccc1)CC[C@@H](CC2)c1nc2ccc(cc2[nH]1)C#N |r,wU:3.2,wD:14.19,(44.12,-48.11,;42.99,-47.06,;41.48,-47.37,;40.72,-46.03,;41.77,-44.89,;43.17,-45.54,;44.5,-44.78,;45.83,-45.57,;47.17,-44.82,;47.18,-43.28,;45.85,-42.49,;44.51,-43.25,;39.98,-47.38,;38.45,-47.41,;37.65,-46.09,;38.38,-44.74,;39.92,-44.71,;36.11,-46.12,;35.23,-47.4,;33.75,-46.95,;32.43,-47.76,;31.08,-47.02,;31.05,-45.47,;32.36,-44.67,;33.71,-45.4,;35.17,-44.89,;29.7,-44.74,;28.35,-43.96,)|
Show InChI InChI=1S/C22H20N4O2/c23-13-15-6-7-18-19(12-15)25-20(24-18)16-8-10-22(11-9-16)14-26(21(27)28-22)17-4-2-1-3-5-17/h1-7,12,16H,8-11,14H2,(H,24,25)/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.316n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417405
PNG
(CHEMBL1289267)
Show SMILES FC(F)(F)Oc1ccc2nc([nH]c2c1)[C@H]1CC[C@@]2(CN(C(=O)O2)c2ccccc2)CC1 |r,wU:17.24,wD:14.15,(-14.1,-12.22,;-12.74,-12.96,;-11.43,-12.16,;-12.7,-11.42,;-12.72,-14.5,;-11.36,-15.24,;-11.32,-16.78,;-9.97,-17.52,;-8.66,-16.71,;-7.17,-17.16,;-6.29,-15.88,;-7.23,-14.65,;-8.69,-15.17,;-10.04,-14.44,;-4.76,-15.85,;-3.96,-17.17,;-2.43,-17.14,;-1.69,-15.79,;-.64,-14.66,;.76,-15.3,;.58,-16.83,;1.71,-17.87,;-.93,-17.13,;2.09,-14.55,;3.41,-15.33,;4.75,-14.58,;4.77,-13.04,;3.44,-12.26,;2.1,-13.01,;-2.48,-14.47,;-4.03,-14.5,)|
Show InChI InChI=1S/C22H20F3N3O3/c23-22(24,25)30-16-6-7-17-18(12-16)27-19(26-17)14-8-10-21(11-9-14)13-28(20(29)31-21)15-4-2-1-3-5-15/h1-7,12,14H,8-11,13H2,(H,26,27)/t14-,21-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.316n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417034
PNG
(CHEMBL1258224)
Show SMILES Fc1ccccc1-c1cnc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3ccccn3)CC2)nc1 |r,wU:13.13,wD:16.22,(-7.82,-7.93,;-8.57,-6.59,;-10.11,-6.57,;-10.86,-5.22,;-10.07,-3.9,;-8.53,-3.92,;-7.79,-5.27,;-6.24,-5.29,;-5.45,-3.96,;-3.91,-3.99,;-3.17,-5.34,;-1.63,-5.36,;-.88,-6.71,;.66,-6.73,;1.45,-5.41,;2.99,-5.43,;3.73,-6.78,;4.87,-5.75,;6.21,-6.52,;5.89,-8.03,;6.92,-9.17,;4.35,-8.19,;7.61,-5.9,;8.86,-6.81,;10.27,-6.19,;10.43,-4.65,;9.17,-3.75,;7.77,-4.37,;2.94,-8.1,;1.41,-8.07,;-3.95,-6.65,;-5.49,-6.64,)|
Show InChI InChI=1S/C24H24FN5O2/c25-20-6-2-1-5-19(20)18-14-28-22(29-15-18)27-13-17-8-10-24(11-9-17)16-30(23(31)32-24)21-7-3-4-12-26-21/h1-7,12,14-15,17H,8-11,13,16H2,(H,27,28,29)/t17-,24-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.316n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417052
PNG
(CHEMBL1258907)
Show SMILES Fc1cccnc1-c1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnn3)CC2)nc1 |r,wU:13.13,wD:16.22,(16.94,-15.12,;16.19,-13.77,;14.65,-13.76,;13.89,-12.41,;14.68,-11.08,;16.22,-11.11,;16.97,-12.46,;18.51,-12.47,;19.27,-13.82,;20.8,-13.84,;21.59,-12.52,;23.13,-12.55,;23.88,-13.89,;25.42,-13.92,;26.21,-12.6,;27.75,-12.62,;28.49,-13.97,;29.63,-12.93,;30.97,-13.71,;30.64,-15.21,;31.67,-16.36,;29.11,-15.37,;32.37,-13.09,;33.62,-14,;35.02,-13.37,;35.19,-11.84,;33.93,-10.93,;32.53,-11.56,;27.7,-15.29,;26.16,-15.26,;20.84,-11.18,;19.31,-11.15,)|
Show InChI InChI=1S/C23H23FN6O2/c24-18-3-1-11-25-21(18)17-5-6-19(27-14-17)26-13-16-7-9-23(10-8-16)15-30(22(31)32-23)20-4-2-12-28-29-20/h1-6,11-12,14,16H,7-10,13,15H2,(H,26,27)/t16-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.316n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417387
PNG
(CHEMBL1289386)
Show SMILES Fc1ccc(cc1)N1C[C@@]2(CC[C@@H](CC2)c2nc3ccc(OC(F)(F)F)cc3[nH]2)OC1=O |r,wU:9.32,wD:12.16,(48.29,-13.3,;46.95,-14.06,;46.93,-15.6,;45.59,-16.35,;44.26,-15.57,;44.28,-14.03,;45.61,-13.28,;42.93,-16.32,;41.53,-15.68,;40.48,-16.81,;39.74,-18.16,;38.21,-18.19,;37.41,-16.88,;38.14,-15.53,;39.68,-15.5,;35.87,-16.91,;34.99,-18.18,;33.51,-17.74,;32.19,-18.54,;30.84,-17.8,;30.81,-16.26,;29.46,-15.52,;29.42,-13.98,;28.07,-13.24,;30.74,-13.18,;29.46,-12.44,;32.12,-15.46,;33.47,-16.19,;34.93,-15.67,;41.24,-18.15,;42.75,-17.85,;43.88,-18.89,)|
Show InChI InChI=1S/C22H19F4N3O3/c23-14-1-3-15(4-2-14)29-12-21(32-20(29)30)9-7-13(8-10-21)19-27-17-6-5-16(11-18(17)28-19)31-22(24,25)26/h1-6,11,13H,7-10,12H2,(H,27,28)/t13-,21-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.316n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
NPY5R


(Chicken)
BDBM82287
PNG
(NPY2-36 | NPY2-36, human | NPY2-36, porcine)
Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1S/C181H278N54O55/c1-16-89(9)141(172(285)226-122(76-133(184)244)162(275)218-117(70-88(7)8)165(278)231-142(90(10)17-2)173(286)232-143(95(15)238)174(287)213-109(33-24-64-200-181(193)194)149(262)212-111(53-56-132(183)243)154(267)210-107(31-22-62-198-179(189)190)150(263)215-114(144(186)257)71-96-37-45-101(239)46-38-96)230-166(279)120(74-99-43-51-104(242)52-44-99)221-161(274)121(75-100-81-195-85-202-100)222-152(265)108(32-23-63-199-180(191)192)211-158(271)116(69-87(5)6)216-147(260)92(12)204-167(280)127(83-236)229-160(273)119(73-98-41-49-103(241)50-42-98)220-159(272)118(72-97-39-47-102(240)48-40-97)219-151(264)106(30-21-61-197-178(187)188)208-145(258)91(11)203-156(269)115(68-86(3)4)217-163(276)124(79-139(253)254)224-155(268)112(55-58-137(249)250)209-146(259)93(13)205-170(283)130-35-26-65-233(130)175(288)94(14)206-157(270)123(78-138(251)252)223-153(266)110(54-57-136(247)248)207-135(246)82-201-169(282)129-34-25-66-234(129)177(290)126(77-134(185)245)227-164(277)125(80-140(255)256)225-171(284)131-36-27-67-235(131)176(289)113(28-18-19-59-182)214-168(281)128(84-237)228-148(261)105-29-20-60-196-105/h37-52,81,85-95,105-131,141-143,196,236-242H,16-36,53-80,82-84,182H2,1-15H3,(H2,183,243)(H2,184,244)(H2,185,245)(H2,186,257)(H,195,202)(H,201,282)(H,203,269)(H,204,280)(H,205,283)(H,206,270)(H,207,246)(H,208,258)(H,209,259)(H,210,267)(H,211,271)(H,212,262)(H,213,287)(H,214,281)(H,215,263)(H,216,260)(H,217,276)(H,218,275)(H,219,264)(H,220,272)(H,221,274)(H,222,265)(H,223,266)(H,224,268)(H,225,284)(H,226,285)(H,227,277)(H,228,261)(H,229,273)(H,230,279)(H,231,278)(H,232,286)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H4,187,188,197)(H4,189,190,198)(H4,191,192,199)(H4,193,194,200)/t89-,90-,91-,92-,93-,94-,95+,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,141-,142-,143-/m0/s1
KEGG

UniProtKB/TrEMBL

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.350n/an/an/an/an/an/an/an/a



Uppsala University

Curated by PDSP Ki Database




J Neurochem 81: 462-71 (2002)


Article DOI: 10.1046/j.1471-4159.2002.00817.x
BindingDB Entry DOI: 10.7270/Q2T72G1G
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417404
PNG
(CHEMBL1289609)
Show SMILES Cc1cccc(n1)N1C[C@@]2(CC[C@@H](CC2)c2nc3ccc(OC(F)(F)F)cc3[nH]2)OC1=O |r,wU:9.32,wD:12.16,(4.72,-25.12,;4.71,-26.66,;6.04,-27.44,;6.02,-28.99,;4.68,-29.74,;3.36,-28.95,;3.37,-27.42,;2.02,-29.7,;.63,-29.06,;-.42,-30.2,;-1.16,-31.54,;-2.7,-31.58,;-3.49,-30.26,;-2.76,-28.91,;-1.22,-28.88,;-5.03,-30.29,;-5.91,-31.56,;-7.39,-31.12,;-8.71,-31.92,;-10.06,-31.19,;-10.09,-29.64,;-11.46,-28.9,;-11.48,-27.37,;-12.84,-26.63,;-10.17,-26.56,;-11.44,-25.82,;-8.78,-28.84,;-7.43,-29.57,;-5.97,-29.06,;.34,-31.53,;1.85,-31.23,;2.98,-32.28,)|
Show InChI InChI=1S/C22H21F3N4O3/c1-13-3-2-4-18(26-13)29-12-21(32-20(29)30)9-7-14(8-10-21)19-27-16-6-5-15(11-17(16)28-19)31-22(23,24)25/h2-6,11,14H,7-10,12H2,1H3,(H,27,28)/t14-,21-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.398n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50416448
PNG
(CHEMBL1209159)
Show SMILES CC(C(=O)N1C[C@H]2[C@@H](CNc3nc(cs3)-c3ccccn3)[C@H]2C1)c1ccccc1 |r|
Show InChI InChI=1S/C23H24N4OS/c1-15(16-7-3-2-4-8-16)22(28)27-12-18-17(19(18)13-27)11-25-23-26-21(14-29-23)20-9-5-6-10-24-20/h2-10,14-15,17-19H,11-13H2,1H3,(H,25,26)/t15?,17-,18+,19-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.398n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 4741-4 (2010)


Article DOI: 10.1016/j.bmcl.2010.06.140
BindingDB Entry DOI: 10.7270/Q2JS9QMP
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50373621
PNG
(CHEMBL403414)
Show SMILES CN(C1CCN(CC1)S(C)(=O)=O)C(=O)Nc1ccc(cc1)-c1cc(F)cc(F)c1
Show InChI InChI=1S/C20H23F2N3O3S/c1-24(19-7-9-25(10-8-19)29(2,27)28)20(26)23-18-5-3-14(4-6-18)15-11-16(21)13-17(22)12-15/h3-6,11-13,19H,7-10H2,1-2H3,(H,23,26)
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.400n/an/an/an/an/an/an/an/a



Schering-Plough Research Institute

Curated by ChEMBL


Assay Description
Displacement of [125]PYY from human chimeric NPY Y5 receptor expressed in CHOK1 cells


Bioorg Med Chem Lett 18: 1146-50 (2008)


Article DOI: 10.1016/j.bmcl.2007.11.132
BindingDB Entry DOI: 10.7270/Q27D2W1W
More data for this
Ligand-Target Pair
NPY5R


(Chicken)
BDBM82286
PNG
(CAS_59763-91-6 | PP, human | PP,SALMON)
Show SMILES [#6]-[#6]-[#6](-[#6])-[#6@H](-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccc(-[#8])cc1)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]\[#7+]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]-[#7]-[#6](-[#7])=[#7+])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#6])-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#8])=O)-[#7]-[#6](=O)-[#6@H](-[#6])-[#7]-[#6](=O)-[#6@H](-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-c1ccc(-[#8])cc1)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#16]-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#8])=O)-[#7]-[#6](=O)-[#6@@H]-1-[#6]-[#6]-[#6]-[#7]-1-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@H](-[#6])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#8])=O)-[#7]-[#6](=O)-[#6](-[#6])-[#7]-[#6](=O)-[#6@@H]-1-[#6]-[#6]-[#6]-[#7]-1-[#6](=O)-[#6@H](-[#6]-c1ccc(-[#8])cc1)-[#7]-[#6](=O)-[#6@@H](-[#7]-[#6](=O)-[#6@@H]-1-[#6]-[#6]-[#6]-[#7]-1-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#8])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#6])-[#6])-[#7]-[#6](=O)-[#6@@H]-1-[#6]-[#6]-[#6]-[#7]-1-[#6](=O)-[#6](-[#6])-[#7])-[#6](-[#6])-[#6])-[#6](-[#6])-[#8])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#7])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#16]-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#6])-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6@@H](-[#6])-[#8])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](-[#7])=O
Show InChI InChI=1S/C185H287N53O54S2/c1-21-91(10)143(175(286)228-125(84-137(190)248)164(275)213-114(63-74-294-20)158(269)221-120(77-89(6)7)167(278)232-144(98(17)239)176(287)217-115(34-25-67-203-185(198)199)178(289)235-69-28-37-131(235)170(281)214-110(33-24-66-202-184(196)197)154(265)218-117(146(191)257)78-100-40-48-104(241)49-41-100)231-168(279)122(80-102-44-52-106(243)53-45-102)224-155(266)109(32-23-65-201-183(194)195)210-153(264)108(31-22-64-200-182(192)193)211-161(272)118(75-87(2)3)222-165(276)126(85-140(253)254)219-149(260)94(13)204-147(258)93(12)206-159(270)121(79-101-42-50-105(242)51-43-101)223-156(267)111(56-59-134(187)245)209-148(259)95(14)205-152(263)113(62-73-293-19)212-163(274)124(83-136(189)247)225-157(268)112(57-60-138(249)250)215-171(282)132-38-30-72-238(132)181(292)145(99(18)240)233-151(262)97(16)207-160(271)123(82-135(188)246)226-166(277)127(86-141(255)256)220-150(261)96(15)208-169(280)129-35-27-71-237(129)180(291)128(81-103-46-54-107(244)55-47-103)229-174(285)142(90(8)9)230-173(284)133-39-29-70-236(133)179(290)116(58-61-139(251)252)216-162(273)119(76-88(4)5)227-172(283)130-36-26-68-234(130)177(288)92(11)186/h40-55,87-99,108-133,142-145,239-244H,21-39,56-86,186H2,1-20H3,(H2,187,245)(H2,188,246)(H2,189,247)(H2,190,248)(H2,191,257)(H,204,258)(H,205,263)(H,206,270)(H,207,271)(H,208,280)(H,209,259)(H,210,264)(H,211,272)(H,212,274)(H,213,275)(H,214,281)(H,215,282)(H,216,273)(H,217,287)(H,218,265)(H,219,260)(H,220,261)(H,221,269)(H,222,276)(H,223,267)(H,224,266)(H,225,268)(H,226,277)(H,227,283)(H,228,286)(H,229,285)(H,230,284)(H,231,279)(H,232,278)(H,233,262)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H4,192,193,200)(H4,194,195,201)(H4,196,197,202)(H4,198,199,203)/p+2/t91?,92?,93-,94-,95-,96?,97-,98+,99?,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,142-,143-,144-,145-/m0/s1
KEGG

UniProtKB/TrEMBL

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.480n/an/an/an/an/an/an/an/a



Uppsala University

Curated by PDSP Ki Database




J Neurochem 81: 462-71 (2002)


Article DOI: 10.1046/j.1471-4159.2002.00817.x
BindingDB Entry DOI: 10.7270/Q2T72G1G
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50379595
PNG
(CHEMBL2013012)
Show SMILES CC(C)S(=O)(=O)NC[C@H]1CC[C@@H](CC1)NC(=O)CN1CCc2cc(Cl)ccc12 |r,wU:8.7,wD:11.14,(11.13,-18.2,;9.8,-17.43,;9.8,-15.89,;8.46,-18.19,;9.22,-19.52,;7.69,-19.52,;7.13,-17.43,;5.8,-18.19,;4.46,-17.42,;3.13,-18.19,;1.8,-17.42,;1.8,-15.88,;3.13,-15.1,;4.46,-15.88,;.47,-15.12,;-.86,-15.89,;-.86,-17.43,;-2.2,-15.12,;-3.53,-15.9,;-3.69,-17.43,;-5.2,-17.75,;-5.97,-16.42,;-7.47,-16.11,;-7.95,-14.65,;-9.46,-14.34,;-6.92,-13.5,;-5.42,-13.82,;-4.94,-15.28,)|
Show InChI InChI=1S/C20H30ClN3O3S/c1-14(2)28(26,27)22-12-15-3-6-18(7-4-15)23-20(25)13-24-10-9-16-11-17(21)5-8-19(16)24/h5,8,11,14-15,18,22H,3-4,6-7,9-10,12-13H2,1-2H3,(H,23,25)/t15-,18-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.5n/an/an/an/an/an/an/an/a



Lundbeck Research USA

Curated by ChEMBL


Assay Description
Displacement of [125I]peptide YY from human NPY5 receptor


Bioorg Med Chem Lett 22: 2167-71 (2012)


Article DOI: 10.1016/j.bmcl.2012.01.117
BindingDB Entry DOI: 10.7270/Q2BV7HNQ
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50353151
PNG
(CHEMBL1829323)
Show SMILES CC(C)S(=O)(=O)NC[C@H]1CC[C@@H](CC1)NC(=O)CN1CCSc2cc(Cl)ccc12 |r,wU:11.14,wD:8.7,(10.22,-17.24,;8.89,-16.47,;8.89,-14.93,;7.56,-17.23,;6.77,-18.56,;8.31,-18.56,;6.22,-16.46,;4.89,-17.23,;3.56,-16.46,;3.56,-14.92,;2.22,-14.14,;.89,-14.92,;.89,-16.46,;2.22,-17.22,;-.45,-14.14,;-1.77,-14.92,;-1.77,-16.46,;-3.11,-14.15,;-4.44,-14.92,;-4.44,-16.47,;-5.78,-17.23,;-7.11,-16.46,;-7.11,-14.93,;-8.45,-14.16,;-8.45,-12.62,;-9.78,-11.85,;-7.12,-11.85,;-5.78,-12.61,;-5.77,-14.16,)|
Show InChI InChI=1S/C20H30ClN3O3S2/c1-14(2)29(26,27)22-12-15-3-6-17(7-4-15)23-20(25)13-24-9-10-28-19-11-16(21)5-8-18(19)24/h5,8,11,14-15,17,22H,3-4,6-7,9-10,12-13H2,1-2H3,(H,23,25)/t15-,17-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.600n/an/an/an/an/an/an/an/a



Lundbeck Research USA, Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]PYY from human NPY5 receptor expressed in thymidine kinase deficient mouse LM cells after 120 mins by scintillation counting


Bioorg Med Chem Lett 21: 5573-6 (2011)


Article DOI: 10.1016/j.bmcl.2011.06.078
BindingDB Entry DOI: 10.7270/Q2TQ61X3
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50015490
PNG
(CHEMBL438945 | H-YPSKPDNPGEDAPAEDMARYYSALRHYINLITR...)
Show InChI InChI=1S/C189H285N55O57S/c1-15-93(7)148(179(295)234-128(81-140(193)254)168(284)226-123(74-92(5)6)171(287)239-149(94(8)16-2)180(296)240-150(99(13)247)181(297)222-115(31-22-67-208-189(202)203)156(272)220-117(56-59-139(192)253)161(277)218-113(29-20-65-206-187(198)199)157(273)224-121(151(195)267)76-101-38-48-107(249)49-39-101)238-172(288)126(79-104-44-54-110(252)55-45-104)229-167(283)127(80-105-86-204-90-210-105)230-159(275)114(30-21-66-207-188(200)201)219-164(280)122(73-91(3)4)225-154(270)96(10)212-173(289)133(88-245)236-166(282)125(78-103-42-52-109(251)53-43-103)228-165(281)124(77-102-40-50-108(250)51-41-102)227-158(274)112(28-19-64-205-186(196)197)216-152(268)95(9)211-155(271)119(62-72-302-14)221-169(285)130(84-146(263)264)232-162(278)118(58-61-144(259)260)217-153(269)97(11)213-176(292)136-33-24-68-241(136)182(298)98(12)214-163(279)129(83-145(261)262)231-160(276)116(57-60-143(257)258)215-142(256)87-209-175(291)135-32-23-70-243(135)185(301)132(82-141(194)255)235-170(286)131(85-147(265)266)233-177(293)138-35-26-71-244(138)184(300)120(27-17-18-63-190)223-174(290)134(89-246)237-178(294)137-34-25-69-242(137)183(299)111(191)75-100-36-46-106(248)47-37-100/h36-55,86,90-99,111-138,148-150,245-252H,15-35,56-85,87-89,190-191H2,1-14H3,(H2,192,253)(H2,193,254)(H2,194,255)(H2,195,267)(H,204,210)(H,209,291)(H,211,271)(H,212,289)(H,213,292)(H,214,279)(H,215,256)(H,216,268)(H,217,269)(H,218,277)(H,219,280)(H,220,272)(H,221,285)(H,222,297)(H,223,290)(H,224,273)(H,225,270)(H,226,284)(H,227,274)(H,228,281)(H,229,283)(H,230,275)(H,231,276)(H,232,278)(H,233,293)(H,234,295)(H,235,286)(H,236,282)(H,237,294)(H,238,288)(H,239,287)(H,240,296)(H,257,258)(H,259,260)(H,261,262)(H,263,264)(H,265,266)(H4,196,197,205)(H4,198,199,206)(H4,200,201,207)(H4,202,203,208)/t93-,94-,95-,96-,97-,98-,99+,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,148-,149-,150-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.600n/an/an/an/an/an/an/an/a



Federal Institute of Technology of Zurich

Curated by PDSP Ki Database




J Biol Chem 275: 36043-8 (2000)


Article DOI: 10.1074/jbc.M000626200
BindingDB Entry DOI: 10.7270/Q2PV6HX1
More data for this
Ligand-Target Pair
NPY5R


(Chicken)
BDBM86028
PNG
(CAS_0 | NSC_0 | PYY, chicken)
Show InChI InChI=1S/C193H290N52O57/c1-18-99(11)80-128(228-167(277)122(59-64-149(257)258)221-165(275)124(61-66-151(261)262)223-180(290)141-37-27-72-242(141)187(297)138(92-247)237-159(269)102(14)211-156(266)101(13)212-169(279)134(88-152(263)264)215-148(256)90-209-179(289)140-36-26-71-241(140)185(295)116(19-2)216-163(273)123(60-65-150(259)260)222-181(291)142-38-28-73-243(142)188(298)139(93-302-76-67-194)238-182(292)143-39-29-74-244(143)189(299)144-40-30-75-245(144)186(296)135(234-155(265)100(12)195)84-109-45-53-114(251)54-46-109)168(278)213-103(15)157(267)217-120(57-62-145(196)253)166(276)229-130(82-107-41-49-112(249)50-42-107)173(283)230-129(81-106-31-21-20-22-32-106)174(284)236-137(91-246)178(288)214-104(16)158(268)225-125(77-95(3)4)170(280)219-117(33-23-68-206-191(199)200)161(271)232-132(86-111-89-205-94-210-111)175(285)231-131(83-108-43-51-113(250)52-44-108)172(282)226-126(78-96(5)6)171(281)233-133(87-147(198)255)176(286)227-127(79-97(7)8)177(287)239-153(98(9)10)183(293)240-154(105(17)248)184(294)224-119(35-25-70-208-193(203)204)160(270)220-121(58-63-146(197)254)164(274)218-118(34-24-69-207-192(201)202)162(272)235-136(190(300)301)85-110-47-55-115(252)56-48-110/h20-22,31-32,41-56,89,94-105,116-144,153-154,246-252H,18-19,23-30,33-40,57-88,90-93,194-195H2,1-17H3,(H2,196,253)(H2,197,254)(H2,198,255)(H,205,210)(H,209,289)(H,211,266)(H,212,279)(H,213,278)(H,214,288)(H,215,256)(H,216,273)(H,217,267)(H,218,274)(H,219,280)(H,220,270)(H,221,275)(H,222,291)(H,223,290)(H,224,294)(H,225,268)(H,226,282)(H,227,286)(H,228,277)(H,229,276)(H,230,283)(H,231,285)(H,232,271)(H,233,281)(H,234,265)(H,235,272)(H,236,284)(H,237,269)(H,238,292)(H,239,287)(H,240,293)(H,257,258)(H,259,260)(H,261,262)(H,263,264)(H,300,301)(H4,199,200,206)(H4,201,202,207)(H4,203,204,208)/t99?,100-,101+,102+,103+,104+,105-,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,153+,154+/m1/s1
KEGG

UniProtKB/TrEMBL

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.620n/an/an/an/an/an/an/an/a



Uppsala University

Curated by PDSP Ki Database




J Neurochem 81: 462-71 (2002)


Article DOI: 10.1046/j.1471-4159.2002.00817.x
BindingDB Entry DOI: 10.7270/Q2T72G1G
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417386
PNG
(CHEMBL1289268)
Show SMILES Fc1ccccc1N1C[C@@]2(CC[C@@H](CC2)c2nc3ccc(OC(F)(F)F)cc3[nH]2)OC1=O |r,wU:9.32,wD:12.16,(21.81,-13.52,;23.13,-14.3,;24.47,-13.55,;25.8,-14.33,;25.78,-15.87,;24.44,-16.62,;23.12,-15.84,;21.78,-16.59,;20.39,-15.95,;19.34,-17.08,;18.6,-18.43,;17.06,-18.46,;16.27,-17.15,;17,-15.79,;18.54,-15.76,;14.73,-17.18,;13.85,-18.45,;12.37,-18.01,;11.05,-18.81,;9.7,-18.07,;9.67,-16.53,;8.32,-15.79,;8.28,-14.25,;6.93,-13.51,;9.59,-13.45,;8.32,-12.71,;10.98,-15.73,;12.33,-16.46,;13.79,-15.94,;20.1,-18.42,;21.61,-18.12,;22.74,-19.16,)|
Show InChI InChI=1S/C22H19F4N3O3/c23-15-3-1-2-4-18(15)29-12-21(32-20(29)30)9-7-13(8-10-21)19-27-16-6-5-14(11-17(16)28-19)31-22(24,25)26/h1-6,11,13H,7-10,12H2,(H,27,28)/t13-,21-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.631n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50416460
PNG
(CHEMBL1209345)
Show SMILES Fc1cc(F)cc(CN2C[C@H]3[C@@H](CNc4nc(cs4)-c4ccccn4)[C@H]3C2)c1 |r|
Show InChI InChI=1S/C21H20F2N4S/c22-14-5-13(6-15(23)7-14)9-27-10-17-16(18(17)11-27)8-25-21-26-20(12-28-21)19-3-1-2-4-24-19/h1-7,12,16-18H,8-11H2,(H,25,26)/t16-,17+,18-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.631n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 4741-4 (2010)


Article DOI: 10.1016/j.bmcl.2010.06.140
BindingDB Entry DOI: 10.7270/Q2JS9QMP
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50416445
PNG
(CHEMBL1209162)
Show SMILES O=C(CCc1ccccc1)N1C[C@H]2[C@@H](CNc3nc(cs3)-c3ccccn3)[C@H]2C1 |r|
Show InChI InChI=1S/C23H24N4OS/c28-22(10-9-16-6-2-1-3-7-16)27-13-18-17(19(18)14-27)12-25-23-26-21(15-29-23)20-8-4-5-11-24-20/h1-8,11,15,17-19H,9-10,12-14H2,(H,25,26)/t17-,18+,19-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.631n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 4741-4 (2010)


Article DOI: 10.1016/j.bmcl.2010.06.140
BindingDB Entry DOI: 10.7270/Q2JS9QMP
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417043
PNG
(CHEMBL1257520)
Show SMILES Cc1ncccc1N1C[C@@]2(CC[C@H](CNc3cnn(c3)-c3ccccc3F)CC2)OC1=O |r,wU:12.13,wD:9.32,(27.95,3.78,;29.2,2.88,;30.61,3.51,;31.86,2.6,;31.69,1.07,;30.29,.45,;29.05,1.35,;27.64,.73,;26.3,1.5,;25.16,.47,;24.42,1.83,;22.88,1.84,;22.08,.52,;20.54,.55,;19.8,1.89,;18.26,1.92,;17.37,3.18,;15.89,2.72,;15.87,1.18,;17.33,.68,;14.61,.3,;13.22,.95,;11.96,.07,;12.1,-1.47,;13.5,-2.12,;14.75,-1.23,;16.15,-1.88,;22.84,-.82,;24.37,-.85,;25.79,-.94,;27.32,-.77,;28.34,-1.92,)|
Show InChI InChI=1S/C24H26FN5O2/c1-17-21(7-4-12-26-17)29-16-24(32-23(29)31)10-8-18(9-11-24)13-27-19-14-28-30(15-19)22-6-3-2-5-20(22)25/h2-7,12,14-15,18,27H,8-11,13,16H2,1H3/t18-,24-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.631n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417403
PNG
(CHEMBL1290038)
Show SMILES Fc1ccc(cc1)N1C[C@@]2(CC[C@@H](CC2)c2nc3ccc(cc3[nH]2)C#N)OC1=O |r,wU:9.29,wD:12.16,(8.45,-40.09,;7.11,-40.85,;7.09,-42.39,;5.75,-43.14,;4.42,-42.35,;4.44,-40.82,;5.77,-40.06,;3.09,-43.11,;1.69,-42.46,;.65,-43.6,;-.1,-44.95,;-1.63,-44.98,;-2.43,-43.66,;-1.7,-42.31,;-.15,-42.28,;-3.96,-43.69,;-4.85,-44.97,;-6.33,-44.52,;-7.64,-45.33,;-8.99,-44.59,;-9.03,-43.05,;-7.72,-42.24,;-6.37,-42.98,;-4.9,-42.46,;-10.38,-42.31,;-11.72,-41.54,;1.41,-44.94,;2.91,-44.64,;4.05,-45.68,)|
Show InChI InChI=1S/C22H19FN4O2/c23-16-2-4-17(5-3-16)27-13-22(29-21(27)28)9-7-15(8-10-22)20-25-18-6-1-14(12-24)11-19(18)26-20/h1-6,11,15H,7-10,13H2,(H,25,26)/t15-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.631n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50417402
PNG
(CHEMBL1289820)
Show SMILES FC(F)(F)c1ccc2nc([nH]c2c1)[C@H]1CC[C@@]2(CN(C(=O)O2)c2ccccc2)CC1 |r,wU:16.23,wD:13.14,(28.53,-36.29,;28.56,-37.83,;27.25,-38.63,;27.22,-37.06,;29.91,-38.57,;29.95,-40.11,;31.3,-40.85,;32.61,-40.05,;34.1,-40.49,;34.98,-39.22,;34.04,-37.99,;32.58,-38.5,;31.22,-37.77,;36.51,-39.19,;37.31,-40.51,;38.84,-40.47,;39.59,-39.12,;40.63,-37.99,;42.03,-38.63,;41.86,-40.16,;42.99,-41.2,;40.35,-40.46,;43.37,-37.88,;44.69,-38.67,;46.03,-37.91,;46.05,-36.37,;44.71,-35.59,;43.38,-36.35,;38.79,-37.81,;37.24,-37.84,)|
Show InChI InChI=1S/C22H20F3N3O2/c23-22(24,25)15-6-7-17-18(12-15)27-19(26-17)14-8-10-21(11-9-14)13-28(20(29)30-21)16-4-2-1-3-5-16/h1-7,12,14H,8-11,13H2,(H,26,27)/t14-,21-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.631n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50380913
PNG
(CHEMBL2016732)
Show SMILES CN([C@H]1CC[C@]2(CC1)OC(=O)c1ccccc21)C(=O)Nc1ccn(n1)-c1ccccc1F |r,wU:2.1,5.8,(21.96,-24.15,;21.92,-25.7,;20.56,-26.43,;20.55,-27.97,;19.23,-28.74,;17.89,-27.96,;17.89,-26.43,;19.23,-25.66,;18.05,-29.5,;16.65,-30.12,;16.32,-31.63,;15.62,-28.98,;14.08,-28.97,;13.32,-27.65,;14.08,-26.32,;15.62,-26.31,;16.39,-27.64,;23.23,-26.5,;23.3,-28.04,;24.56,-25.72,;25.85,-26.57,;27.3,-26.02,;28.27,-27.22,;27.42,-28.51,;25.93,-28.1,;28.17,-29.86,;27.38,-31.18,;28.13,-32.53,;29.67,-32.55,;30.46,-31.21,;29.71,-29.87,;30.49,-28.55,)|
Show InChI InChI=1S/C24H23FN4O3/c1-28(23(31)26-21-12-15-29(27-21)20-9-5-4-8-19(20)25)16-10-13-24(14-11-16)18-7-3-2-6-17(18)22(30)32-24/h2-9,12,15-16H,10-11,13-14H2,1H3,(H,26,27,31)/t16-,24+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.700n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]PPY from human recombinant NPYY5 receptor expressed in insect Sf9 membranes


Bioorg Med Chem Lett 22: 2738-43 (2012)


Article DOI: 10.1016/j.bmcl.2012.02.098
BindingDB Entry DOI: 10.7270/Q2154J34
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5 ( NPY Y5)


(Homo sapiens (Human))
BDBM50015490
PNG
(CHEMBL438945 | H-YPSKPDNPGEDAPAEDMARYYSALRHYINLITR...)
Show InChI InChI=1S/C189H285N55O57S/c1-15-93(7)148(179(295)234-128(81-140(193)254)168(284)226-123(74-92(5)6)171(287)239-149(94(8)16-2)180(296)240-150(99(13)247)181(297)222-115(31-22-67-208-189(202)203)156(272)220-117(56-59-139(192)253)161(277)218-113(29-20-65-206-187(198)199)157(273)224-121(151(195)267)76-101-38-48-107(249)49-39-101)238-172(288)126(79-104-44-54-110(252)55-45-104)229-167(283)127(80-105-86-204-90-210-105)230-159(275)114(30-21-66-207-188(200)201)219-164(280)122(73-91(3)4)225-154(270)96(10)212-173(289)133(88-245)236-166(282)125(78-103-42-52-109(251)53-43-103)228-165(281)124(77-102-40-50-108(250)51-41-102)227-158(274)112(28-19-64-205-186(196)197)216-152(268)95(9)211-155(271)119(62-72-302-14)221-169(285)130(84-146(263)264)232-162(278)118(58-61-144(259)260)217-153(269)97(11)213-176(292)136-33-24-68-241(136)182(298)98(12)214-163(279)129(83-145(261)262)231-160(276)116(57-60-143(257)258)215-142(256)87-209-175(291)135-32-23-70-243(135)185(301)132(82-141(194)255)235-170(286)131(85-147(265)266)233-177(293)138-35-26-71-244(138)184(300)120(27-17-18-63-190)223-174(290)134(89-246)237-178(294)137-34-25-69-242(137)183(299)111(191)75-100-36-46-106(248)47-37-100/h36-55,86,90-99,111-138,148-150,245-252H,15-35,56-85,87-89,190-191H2,1-14H3,(H2,192,253)(H2,193,254)(H2,194,255)(H2,195,267)(H,204,210)(H,209,291)(H,211,271)(H,212,289)(H,213,292)(H,214,279)(H,215,256)(H,216,268)(H,217,269)(H,218,277)(H,219,280)(H,220,272)(H,221,285)(H,222,297)(H,223,290)(H,224,273)(H,225,270)(H,226,284)(H,227,274)(H,228,281)(H,229,283)(H,230,275)(H,231,276)(H,232,278)(H,233,293)(H,234,295)(H,235,286)(H,236,282)(H,237,294)(H,238,288)(H,239,287)(H,240,296)(H,257,258)(H,259,260)(H,261,262)(H,263,264)(H,265,266)(H4,196,197,205)(H4,198,199,206)(H4,200,201,207)(H4,202,203,208)/t93-,94-,95-,96-,97-,98-,99+,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,148-,149-,150-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
PubMed
0.730n/an/an/an/an/an/an/an/a



Bayer Corporation

Curated by PDSP Ki Database




J Biol Chem 271: 26315-9 (1996)


BindingDB Entry DOI: 10.7270/Q20G3HPR
More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 1423 total )  |  Next  |  Last  >>
Jump to: